Summary of Significant Accounting Policies - Schedule of Company Revenue and Adjusted EBITDA by Segment (Details) - USD ($) $ in Thousands		3 Months Ended				6 Months Ended
		Sep. 30, 2022	Jun. 30, 2022	Sep. 30, 2021	Jun. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Segment Adjusted EBITDA
Total Adjusted EBITDA		$ 29,655		$ (29,683)		$ (79,369)	$ (56,959)
Net income (loss)		(66,065)	$ (89,532)	(16,524)	$ (42,026)	(155,597)	(58,550)
Adjustments
Interest (income) expense, net		(1,392)		(92)		(1,637)	(136)
Other income (expense), net		687		(3)		1,122	(17)
Change in fair value of warrant liabilities		0		(29,828)		0	(29,294)
Income tax benefit		(1,271)		0		(1,525)	0
Depreciation and Amortization		5,152		4,871		10,256	9,508
Amortization Of Acquired Intangible Assets		4,267		0		8,582	0
Stock-based compensation expense		28,967		10,427		59,430	20,064
Acquisition-related costs	[1]	0		1,466		0	1,466
Total Adjusted EBITDA		(29,655)		(29,683)		(79,369)	(56,959)
Consumer And Research Services [Member]
Segment Revenue
Total Revenue		75,659		55,204		140,172	114,443
Segment Adjusted EBITDA
Total Adjusted EBITDA		2,324		(760)		(14,673)	(1,265)
Therapeutics
Segment Revenue
Total Revenue	[2]	75,659		55,204		140,172	114,443
Segment Adjusted EBITDA
Total Adjusted EBITDA		(18,663)		(18,828)		(37,128)	(37,131)
Unallocated Corporate [Member]
Segment Adjusted EBITDA
Total Adjusted EBITDA		$ (13,316)		$ (10,095)		$ (27,568)	$ (18,563)

[1] For the three and six months ended September 30, 2021, acquisition-related costs primarily consisted of advisory, legal and consulting fees.

[2] There was no Therapeutics revenue for the three and six months ended September 30, 2022 and 2021.